DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 189 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 0.96 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $74 | -9.8% | 5,841 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $82 | -5.7% | 5,841 | +4.3% | 0.00% | 0.0% |
| Q1 2023 | $87 | -15.5% | 5,600 | -11.3% | 0.00% | 0.0% |
| Q4 2022 | $103 | -99.9% | 6,313 | +2.5% | 0.00% | 0.0% |
| Q3 2022 | $114,000 | +40.7% | 6,161 | +0.5% | 0.00% | 0.0% |
| Q2 2022 | $81,000 | +42.1% | 6,130 | -1.1% | 0.00% | – |
| Q1 2022 | $57,000 | -75.2% | 6,196 | -8.5% | 0.00% | -100.0% |
| Q3 2021 | $230,000 | -12.2% | 6,769 | -5.6% | 0.00% | 0.0% |
| Q2 2021 | $262,000 | +6.5% | 7,170 | +30.9% | 0.00% | -77.8% |
| Q1 2021 | $246,000 | -27.6% | 5,479 | -8.0% | 0.01% | -30.8% |
| Q4 2020 | $340,000 | +13.7% | 5,956 | +2.4% | 0.01% | 0.0% |
| Q3 2020 | $299,000 | -16.2% | 5,819 | -2.8% | 0.01% | -23.5% |
| Q2 2020 | $357,000 | +55.9% | 5,986 | +62.4% | 0.02% | +325.0% |
| Q4 2019 | $229,000 | – | 3,687 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,209,571 | $72,236,000 | 20.73% |
| SV Health Investors, LLC | 449,951 | $26,871,000 | 18.64% |
| Redmile Group, LLC | 4,978,941 | $297,342,000 | 5.49% |
| Sunesis Advisors, LLC | 96,299 | $5,751,000 | 5.29% |
| Eversept Partners, LP | 418,652 | $25,001,897 | 3.43% |
| Opaleye Management Inc. | 222,000 | $13,081,000 | 2.64% |
| Avoro Capital Advisors LLC | 1,860,000 | $111,079,000 | 2.20% |
| SPHERA FUNDS MANAGEMENT LTD. | 282,965 | $16,899,000 | 1.59% |
| SECTORAL ASSET MANAGEMENT INC | 224,359 | $13,399,000 | 1.23% |
| Artal Group S.A. | 650,000 | $38,818,000 | 1.09% |